Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE).

Reck, M; Thomas, M; Kropf-Sanchen, C; Mezger, J; Socinski, M A; Depenbrock, H; Soldatenkova, V; Brown, J; Krause, T; Thatcher, Nick

dc.contributor.author	Reck, M
dc.contributor.author	Thomas, M
dc.contributor.author	Kropf-Sanchen, C
dc.contributor.author	Mezger, J
dc.contributor.author	Socinski, M A
dc.contributor.author	Depenbrock, H
dc.contributor.author	Soldatenkova, V
dc.contributor.author	Brown, J
dc.contributor.author	Krause, T
dc.contributor.author	Thatcher, Nick
dc.date.accessioned	2016-12-16T15:35:35Z
dc.date.available	2016-12-16T15:35:35Z
dc.date.issued	2016
dc.identifier.citation	Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE). 2016, 39(9): 539-47 Oncol Res Treat	en
dc.identifier.issn	2296-5262
dc.identifier.pmid	27614872
dc.identifier.doi	10.1159/000448085
dc.identifier.uri	http://hdl.handle.net/10541/620051
dc.description.abstract	In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. We explored data for the German subpopulation (N = 96) of SQUIRE patients with EGFR-expressing tumors.
dc.language.iso	en	en
dc.rights	Archived with thanks to Oncology research and treatment	en
dc.title	Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE).	en
dc.type	Article	en
dc.identifier.journal	Oncology research and treatment	en
refterms.dateFOA	2018-12-17T14:46:13Z
html.description.abstract	In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. We explored data for the German subpopulation (N = 96) of SQUIRE patients with EGFR-expressing tumors.